Shrestha Saneep, Shakya Shrestha Upasana, Priyanka Jyoti, Shrestha Pragya
Department of Community Medicine, Universal College of Medical Science and Teaching Hospital, Tribhuvan University, Bhairahawa, Rupandehi, Nepal.
Care Nepal, USAID Adolescent Reproductive Health, Birendranagar, Surkhet, Nepal.
AIDS Res Treat. 2023 Oct 23;2023:3526208. doi: 10.1155/2023/3526208. eCollection 2023.
Depression is a common mental disorder and is a leading cause of disability globally. Depressive symptoms among people living with HIV can be a significant barrier to ART initiation and thus lead to poor ART adherence. Global studies have found the prevalence of depressive symptoms among people living with HIV ranges from 12 to 63%. The real scenario of Nepal still needs to be explored. Thus, this study aimed to identify the prevalence and predictors of depression in individuals with HIV.
An institutional-based cross-sectional study was carried out from August to December 2020 among 406 people living with HIV attending ART centers in Lumbini province. Participants were selected using a systematic random sampling technique and surveyed with a structured questionnaire consisting of sociodemographic variables, HIV AIDS-related variables, and 21 items Beck Depression Inventory tool. The odds ratio was used as the ultimate measure of association, with a 95% confidence interval computed to establish statistical significance. A multivariate regression analysis was carried out to identify the final predictors of depressive symptoms.
The study found that 26.8% of the respondents had depressive symptoms. Those who were literate (AOR = 0.24, 95% CI: 0.10-0.61), in the poorest wealth quintile (AOR = 7.28, 95% CI: 2.22-23.87), initiated ART within 12 months (AOR = 1.88, 95% CI: 1.03-3.42), had CD4 cell counts below 200 (AOR = 2.50, 95% CI: 1.54-4.06), and had a time difference of 3 months or less between HIV diagnosis and ART initiation (AOR = 0.50, 95% CI: 0.29-0.86) were independently associated with depressive symptoms.
Routine screening for depressive symptoms should be integrated into national HIV prevention and control programs for people living with HIV. An enabling environment should be created to facilitate the rapid enrollment of individuals newly diagnosed with HIV in ART services, thereby reducing the time gap between HIV diagnosis and ART initiation.
抑郁症是一种常见的精神障碍,是全球致残的主要原因。艾滋病毒感染者的抑郁症状可能是开始抗逆转录病毒治疗(ART)的重大障碍,从而导致抗逆转录病毒治疗依从性差。全球研究发现,艾滋病毒感染者中抑郁症状的患病率在12%至63%之间。尼泊尔的实际情况仍有待探索。因此,本研究旨在确定艾滋病毒感染者中抑郁症的患病率及其预测因素。
2020年8月至12月,在蓝毗尼省接受抗逆转录病毒治疗的406名艾滋病毒感染者中开展了一项基于机构的横断面研究。采用系统随机抽样技术选取参与者,并使用一份结构化问卷进行调查,问卷包括社会人口统计学变量、艾滋病毒/艾滋病相关变量以及21项贝克抑郁量表工具。比值比用作关联的最终衡量指标,并计算95%置信区间以确定统计学显著性。进行多因素回归分析以确定抑郁症状的最终预测因素。
研究发现,26.8%的受访者有抑郁症状。识字者(调整后比值比[AOR]=0.24,95%置信区间:0.10-0.61)、处于最贫困财富五分位数者(AOR=7.28,95%置信区间:2.22-23.87)、在12个月内开始抗逆转录病毒治疗者(AOR=1.88,95%置信区间:1.03-3.42)、CD4细胞计数低于200者(AOR=2.50,95%置信区间:1.54-4.06)以及艾滋病毒诊断与开始抗逆转录病毒治疗之间的时间差为3个月或更短者(AOR=0.50,95%置信区间:0.29-0.86)与抑郁症状独立相关。
应将抑郁症状的常规筛查纳入国家艾滋病毒预防和控制项目,以针对艾滋病毒感染者。应营造有利环境,以促进新诊断出艾滋病毒的个体快速纳入抗逆转录病毒治疗服务,从而缩短艾滋病毒诊断与开始抗逆转录病毒治疗之间的时间间隔。